{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate+tablets", "query": { "intervention": "Abiraterone acetate tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 68, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T17:30:05.302Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04628988", "title": "A Study of CC-90011 and Comparators in Participants With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "CC-90011", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2021-07-28", "completion_date": "2023-05-26", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628988" }, { "nct_id": "NCT00600535", "title": "A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "Stage 1 Group 1: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 1 Group 2: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 2: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 3: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 3: glucocorticoid", "type": "DRUG" }, { "name": "Stage 4: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 4: glucocorticoid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 31, "start_date": "2007-07", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-04-17", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600535" }, { "nct_id": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies", "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "AZD4635", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 313, "start_date": "2016-06-17", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740985" }, { "nct_id": "NCT01717053", "title": "Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Androgen deprivation", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 37, "start_date": "2014-01-17", "completion_date": "2021-08-31", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 3, "location_summary": "Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01717053" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT02230046", "title": "Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Abiraterone acetate (Treatment A)", "type": "DRUG" }, { "name": "Abiraterone acetate (Treatment B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 102, "start_date": "2014-10", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02230046" }, { "nct_id": "NCT04748042", "title": "Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Castrate Sensitive Prostate Cancer", "Oligometastatic Disease" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "External Beam Radiotherapy", "type": "RADIATION" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "2021-05-28", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04748042" }, { "nct_id": "NCT04221542", "title": "Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AMG 509", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 479, "start_date": "2020-03-04", "completion_date": "2032-03-21", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 25, "location_summary": "Duarte, California • Fullerton, California • San Francisco, California + 22 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04221542" }, { "nct_id": "NCT00924469", "title": "A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2009-11", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2013-04-17", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Wenatchee", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924469" }, { "nct_id": "NCT01650194", "title": "A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 60, "start_date": "2012-07-09", "completion_date": "2018-01-04", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-24T17:30:05.302Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01650194" } ] }